Update on Endothelin Receptor Antagonists in Hypertension

被引:0
作者
Michel Burnier
机构
[1] Centre Hospitalier Universitaire Vaudois,Department of Medicine, Service of Nephrology and Hypertension
来源
Current Hypertension Reports | 2018年 / 20卷
关键词
Antagonists; Experimental hypertension; Resistant hypertension; Renal; Proteinuria;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 241 条
[1]  
Yanagisawa M(1988)A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 411-415
[2]  
Kurihara H(2016)Endothelin Pharmacol Rev 68 357-418
[3]  
Kimura S(2002)International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature Pharmacol Rev 54 219-226
[4]  
Tomobe Y(1991)Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor Circulation 83 469-475
[5]  
Kobayashi M(2015)Vascular effects of endothelin receptor antagonists depends on their selectivity for ETA versus ETB receptors and on the functionality of endothelial ETB receptors J Cardiovasc Pharmacol 66 332-337
[6]  
Mitsui Y(2016)Global overexpression of ET-1 decreases blood pressure—a systematic review and meta-analysis of ET-1 transgenic mice Kidney Blood Press Res 41 770-780
[7]  
Yazaki Y(2004)Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction Circulation 110 2233-2240
[8]  
Goto K(2015)Endothelin-1 critically influences cardiac function via superoxide-MMP9 cascade Proc Natl Acad Sci U S A 112 5141-5146
[9]  
Masaki T(2005)Vascular endothelin in hypertension Vasc Pharmacol 43 19-29
[10]  
Davenport AP(1996)Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension Hypertension (Dallas, Tex: 1979) 28 652-655